VYNE Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
YARW$15.79+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Shareholders’ Equity
| Common stock · Additional paid-incapital · Accumulatedother comprehensiveincome (loss) · Accumulated deficit · Total Shareholders' Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number of shares · Amounts · Amounts | ||||||||
| BALANCE AT DECEMBER 31, 2023 | 14,098,888 | $1 | $780,044 | $26 | $(691,336) | $88,735 | ||
| CHANGES DURING 2024: | ||||||||
| Net loss | — | — | — | (39,834) | (39,834) | |||
| Vesting of restricted stock units, net of withholding for tax, and shares issued under employee share purchase plan | 91,302 | — | (112) | — | — | (112) | ||
| Share-based compensation | — | — | 3,303 | — | — | 3,303 | ||
| Cashless exercise of pre-funded warrants | 639,823 | — | — | — | — | — | ||
| Unrealized losses from marketable securities | — | — | — | (6) | — | (6) | ||
| BALANCE AT DECEMBER 31, 2024 | 14,830,013 | $1 | $783,235 | $20 | $(731,170) | $52,086 | ||
| CHANGES DURING 2025: | ||||||||
| Net loss | — | — | — | — | (26,483) | (26,483) | ||
| Vesting of restricted stock units, net of withholding for tax, and shares issued under employee share purchase plan | 199,682 | — | (128) | — | — | (128) | ||
| Share-based compensation | — | — | 2,308 | — | — | 2,308 | ||
| Cashless exercise of pre-funded warrants | 18,293,476 | 2 | (2) | — | — | — | ||
| Unrealized losses from marketable securities | — | — | — | (18) | — | (18) | ||
| BALANCE AT DECEMBER 31, 2025 | 33,323,171 | $3 | $785,413 | $2 | $(757,653) | $27,765 | ||
The accompanying notes are an integral part of these consolidated financial statements
F - 4
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.